NCT03553615撤回2 期
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- DLQI
研究概览
简要总结
This pilot trial studies how well a novel oral therapeutic agent performs to treat patients with atopic dermatitis, particularly facial dermatitis.
详细描述
OBJECTIVES:
I. Overall response rate of atopic dermatitis in subjects as assessed using Dermatology Life Quality Index (a 10 question questionnaire used to measure the impact of skin disease on the quality of life of an affected person)
SECONDARY OBJECTIVES:
I. , Eczema Area and Severity Index (EASI), Total Severity Scoring (TSS) II. Safety assessment after 8 weeks with 4 weeks of oral treatment. III. VAS (Visual Analogue Scale, an instrument for the assessment of pruritus) at baseline through eight weeks.
OUTLINE:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have at least one lesion of atopic dermatitis (At least 1% Body surface Area).
- •18 years of age or older.
- •Must be willing to take oral ivermectin once weekly for 4 weeks and monitor over 8 weeks.
- •For women of child bearing potential, a negative urine pregnancy test
- •Women of child bearing potential are expected to use an effective method of birth control while participating in the study and for 1 month after taking the last dose.
- •For male subjects with female partners of childbearing potential, agreement to use adequate contraception while participating in the study and for 1 month after taking the last dose.
- •Has signed and dated the current Institutional Review Board approved informed consent document.
- •Must be able to read and speak English fluently.
排除标准
- •Is currently participating or has participated in another interventional clinical study in the past 2 weeks;
- •Is age <18 years old.
- •Has had known or previous hypersensitivity or allergic reactions to oral ivermectin before;
- •Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the study results;
- •Taking any medication known to interact with ivermectin like Dasabuvir (theoretical) or warfarin (probable).
- •Is planning a trip to a sunny climate, to use tanning booths or use other UV sources throughout the course of this study;
- •Has a history of hypersensitivity to any substance in investigational preparation;
- •Has any clinically significant medical condition or laboratory abnormality that would, in the opinion of the Investigator, put the patient at undue risk or interfere with the interpretation of the study results;
- •Is currently pregnant or breastfeeding.
- •Has other skin conditions that might interfere with Atopic Dermatitis diagnosis and/or evaluation (i.e. psoriasis current active viral, bacterial and fungal skin infections) as assessed by the Investigator;
- •Any other condition or factor the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation
- •History of congestive heart failure; cardiac arrhythmias; or other findings of ventricular dysfunction.
- •History of current evidence of malabsorption or liver disease.
- •Cannot read and speak English fluently.
- •Does not have at least 1% body surface area with lesional atopic dermatitis
研究组 & 干预措施
Oral treatment
Experimental
12mg oral ivermectin treatment taken once a week for four weeks
干预措施: Ivermectin Pill (Drug)
结局指标
主要结局
DLQI
时间窗: 8 weeks
Patient Dermatology Life Quality Index
次要结局
- EASI(8 weeks)
- IGA(8 weeks)
- VAS for Pruritis(8 weeks)
- TSS(8 weeks)
研究者
Kavita Sarin
Assistant Professor of Dermatology
Stanford University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial AcneAcneNCT00725439Stiefel, a GSK Company16
已完成
1 期
An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon ResectionRecurrent Clostridioides Difficile InfectionColonic SurgeryNCT06692179University of Minnesota21
招募中
早期 1 期
Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like SyndromeCRS - Cytokine Release SyndromeHLHNCT05306080University of Pennsylvania10
Unknown
2 期
Pilot Open Label Clinical Trial With Abatacept in Ankylosing SpondylitisAnkylosing SpondylitisNCT00558506Charite University, Berlin, Germany30
已完成
3 期
Treatment of Patients With Nephrogenic Systemic Fibrosis With GlivecNephrogenic Systemic FibrosisNCT00981942University of Aarhus10